Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 9OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Endometrial Neoplasms 2Ovarian Neoplasms 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1198Oxaliplatin 1160Capecitabine 1142Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Interventional × LY3023414 × Clear all
NCT03675893 2025-06-15

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Dana-Farber Cancer Institute

Phase 2 Recruiting
180 enrolled
Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

NCT02549989 2023-02-22

Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
28 enrolled 12 charts
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡